Zacks Investment Research upgraded shares of ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) from a hold rating to a buy rating in a research note issued to investors on Tuesday morning. The firm currently has $0.25 target price on the stock.

According to Zacks, “ESSA Pharma Inc. is a pharmaceutical company. The company focused on the development of small molecule drugs for the treatment of cancer, with focus on advanced prostate cancer. ESSA Pharma Inc. is based in Vancouver, Canada. “

Shares of ESSA Pharma (NASDAQ EPIX) remained flat at $$0.21 during midday trading on Tuesday. 128,400 shares of the stock traded hands, compared to its average volume of 120,540. The company has a current ratio of 1.26, a quick ratio of 1.26 and a debt-to-equity ratio of -1.32. The stock has a market capitalization of $6.11, a PE ratio of -1.31 and a beta of 2.09. ESSA Pharma has a 1-year low of $0.15 and a 1-year high of $3.59.

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last posted its quarterly earnings data on Monday, December 11th. The company reported ($0.09) earnings per share for the quarter. equities research analysts predict that ESSA Pharma will post -0.49 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “ESSA Pharma (EPIX) Upgraded at Zacks Investment Research” was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at

ESSA Pharma Company Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.

Get a free copy of the Zacks research report on ESSA Pharma (EPIX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with's FREE daily email newsletter.